Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Atypon full text link Atypon Free PMC article
Full text links

Actions

Share

.2015 Feb 17;112(7):2257-62.
doi: 10.1073/pnas.1423573112. Epub 2015 Feb 2.

Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson's disease

Affiliations

Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson's disease

Jose A Santiago et al. Proc Natl Acad Sci U S A..

Abstract

Environmental and genetic factors are likely to be involved in the pathogenesis of Parkinson's disease (PD), the second most prevalent neurodegenerative disease among the elderly. Network-based metaanalysis of four independent microarray studies identified the hepatocyte nuclear factor 4 alpha (HNF4A), a transcription factor associated with gluconeogenesis and diabetes, as a central regulatory hub gene up-regulated in blood of PD patients. In parallel, the polypyrimidine tract binding protein 1 (PTBP1), involved in the stabilization and mRNA translation of insulin, was identified as the most down-regulated gene. Quantitative PCR assays revealed that HNF4A and PTBP1 mRNAs were up- and down-regulated, respectively, in blood of 51 PD patients and 45 controls nested in the Diagnostic and Prognostic Biomarkers for Parkinson's Disease. These results were confirmed in blood of 50 PD patients compared with 46 healthy controls nested in the Harvard Biomarker Study. Relative abundance of HNF4A mRNA correlated with the Hoehn and Yahr stage at baseline, suggesting its clinical utility to monitor disease severity. Using both markers, PD patients were classified with 90% sensitivity and 80% specificity. Longitudinal performance analysis demonstrated that relative abundance of HNF4A and PTBP1 mRNAs significantly decreased and increased, respectively, in PD patients during the 3-y follow-up period. The inverse regulation of HNF4A and PTBP1 provides a molecular rationale for the altered insulin signaling observed in PD patients. The longitudinally dynamic biomarkers identified in this study may be useful for monitoring disease-modifying therapies for PD.

Keywords: HNF4A; PTBP1; Parkinson's disease; blood biomarkers; network analysis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Network-based and transcriptomic metaanalysis. (A) Four independent microarray datasets were downloaded from the GEO and preprocessed in INMEX where metaanalysis was undertaken using the Fisher’s method. Datasets were subsequently uploaded into NetworkAnalyst to perform network and functional analysis and to identify key regulatory hub genes across the multiple microarray studies. Finally, the most significant genes were evaluated as biomakers for PD in blood samples obtained from two independent cohorts of patients. (B) Venn diagram of differentially expressed genes identified from the metaanalysis (Meta-DE) and those from each individual microarray analysis (Individual-DE). (C) Heat map representation of the top 20 differentially expressed genes across different microarrays identified from the metaanalysis (row-wise comparison). The heat map was rescaled to prevent domination by study-specific effects. HC, healthy controls; PD, Parkinson’s disease.
Fig. 2.
Fig. 2.
Network analysis of differentially expressed genes in blood of PD patients. (A) Zero-order interaction network of genes up-regulated in blood of PD patients (red). (B) Zero-order interaction network of genes down-regulated in blood of PD patients (green).
Fig. 3.
Fig. 3.
Evaluation of HNF4A and PTBP1 mRNAs as biomarkers for PD at baseline. (A) Relative abundance ofHNF4A mRNA in blood of PD patients (black circles) compared with HCs (white circles) in samples from the PROBE cohort. (B) Replication of biomarker expression in an independent set of samples from patients enrolled in the HBS study. (C) Relative abundance ofPTBP1 mRNA in blood of PD patients compared with HC in samples from the PROBE cohort. (D) Replication ofPTBP1 mRNA expression in an independent set of samples from patients enrolled in the HBS study. Relative abundance of each biomarker was calculated usingGAPDH as a reference gene and HC as calibrator. A Studentt test (two-tailed) was used to estimate the significance between PD cases and controls. Error bars represent 95% confidence intervals.
Fig. 4.
Fig. 4.
Biomarker correlation analysis. (Upper) Pearson correlation analysis betweenHNF4A mRNA andPTBP1 mRNA in blood of PD patients (black circles) and HC (white circles) in samples from PROBE and HBS. (Lower) Correlation analysis between HNF4A mRNA and Hoehn and Yahr scale in PD patients from both cohorts. Solid lines represent the linear regression of the data and dashed lines indicate the 95% confidence of intervals.
Fig. 5.
Fig. 5.
Longitudinal performance ofHNF4A andPTBP1 mRNAs in the HBS study. (A) Individual trajectories for the relative abundance ofHNF4A mRNA over time for HC (blue) and PD patients (red) in the HBS study. (B) AverageHNF4A mRNA expression in PD patients compared with HCs calculated via linear mixed-effects regression analysis adjusting for sex, age, and BMI. (C) Individual trajectories for the relative abundance ofPTBP1 mRNA over time for HCs and PD patients. (D) AveragePTBP1 mRNA expression in PD patients compared with HCs calculated via linear mixed-effects regression analysis. Red and blue lines denote PD patients and HCs, respectively. T0 and T2 indicate baseline and 3-y follow-up period, respectively. Post hoc pair-wise comparisons were performed using a Tukey test (**P = 0.0001, *P = 0.001). Error bars represent SE.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Scherzer CR, et al. Molecular markers of early Parkinson’s disease based on gene expression in blood. Proc Natl Acad Sci USA. 2007;104(3):955–960. - PMC - PubMed
    1. Potashkin JA, Santiago JA, Ravina BM, Watts A, Leontovich AA. Biosignatures for Parkinson’s disease and atypical parkinsonian disorders patients. PLoS ONE. 2012;7(8):e43595. - PMC - PubMed
    1. Santiago JA, Scherzer CR, Potashkin JA. Harvard Biomarker Study Specific splice variants are associated with Parkinson’s disease. Mov Disord. 2013;28(12):1724–1727. - PMC - PubMed
    1. Ding H, et al. Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology. 2013;81(17):1531–1537. - PMC - PubMed
    1. Chen-Plotkin AS, et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol. 2011;69(4):655–663. - PMC - PubMed

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full text links
Atypon full text link Atypon Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp